CMV in kidney transplants in the tacrolimus-mycophenolate era.
Service de néphrologie, Hôpital Maisonneuve-Rosemont and Université de Montréal, Montréal, Canada.
J F
JF
Cailhier
A
A
Boucher
C
C
Béliveau
L
L
Poirier
J
J
Delorme
K
K
Weiss
M
M
Laverdière
M J
MJ
Hébert
V
V
Pichette
R
R
Dandavino
D000998:Antiviral Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects*
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D015774:Ganciclovir; D016559:Tacrolimus